The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis

Thyroid

Volumn 21, Issue 8, 2011, Pages 897-906

  Ma, Risheng ^a   Morshed, Syed ^a   Latif, Rauf ^a   Zaidi, Mone ^a   Davies, Terry F ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCITONIN RECEPTOR; CARBONATE DEHYDRATASE II; CATHEPSIN K; COLONY STIMULATING FACTOR 1; DEXAMETHASONE; GELATINASE B; IMMUNOGLOBULIN G; MESSENGER RNA; NEUTRALIZING ANTIBODY; OCTAMER TRANSCRIPTION FACTOR 4; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR REX1; TRANSCRIPTION FACTOR SOX2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D;

ANIMAL CELL; ARTICLE; BONE REMODELING; CASE REPORT; CELL RENEWAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; EMBRYONIC STEM CELL; EXPERIMENTAL MODEL; GENE EXPRESSION; GRAVES DISEASE; HUMAN; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELL DIFFERENTIATION; DEXAMETHASONE; EMBRYONIC STEM CELLS; HOMOZYGOTE; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MICE, TRANSGENIC; OSTEOCLASTS; RANK LIGAND; RECEPTORS, THYROTROPIN; THYROTROPIN; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN D;

EID: 79961195302     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2010.0457     Document Type: Article

References (33)

1. Ross DS 1994 Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 4:319-326. (Pubitemid 24295429)
2. Biondi B, Cooper DS 2008 The clinical significance of subclinical thyroid dysfunction. Endocr Rev 29:76-131. (Pubitemid 351252748)
3. Zaidi M, Davies TF, Zallone A, Blair HC, Iqbal J, Moonga SS, Mechanick J, Sun L 2009 Thyroid-stimulating hormone, thyroid hormones, and bone loss. Curr Osteoporos Rep 7:47-52.
4. Kim BJ, Lee SH, Bae SJ, Kim HK, Choe JW, Kim HY, Koh JM, Kim GS 2010 The association between serum thyrotropin (TSH) levels and bone mineral density in healthy euthyroid men. Clin Endocrinol (Oxf) 73:396-403.
5. Mazziotti G, Porcelli T, Patelli I, Vescovi PP, Giustina A 2010 Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone 46:747-751.
6. Mundy GR, Shapiro JL, Bandelin JG, Canalis EM, Raisz LG 1976 Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 58:529-534.
7. Gogakos AI, Duncan Bassett JH, Williams GR 2010 Thyroid and bone. Arch Biochem Biophys 503:129-136.
8. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M 2003 TSH is a negative regulator of skeletal remodeling. Cell 115:151-162. (Pubitemid 37329579)
9. Bassett JH, Williams AJ, Murphy E, Boyde A, Howell PG, Swinhoe R, Archanco M, Flamant F, Samarut J, Costagliola S, Vassart G, Weiss RE 2008A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism. Mol Endocrinol 22:501-512. (Pubitemid 351185945)
10. Hase H, Ando T, Eldeiry L, Brebene A, Peng Y, Liu L, Amano H, Davies TF, Sun L, Zaidi M, Abe E 2006 TNFalpha mediates the skeletal effects of thyroid-stimulating hormone. Proc Natl Acad Sci U S A 103:12849-12854. (Pubitemid 44298650)
11. Sampath TK, Simic P, Sendak R, Draca N, Bowe AE, O'Brien S, Schiavi SC, McPherson JM, Vukicevic S 2007 Thyroidstimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. J Bone Miner Res 22:849-859. (Pubitemid 351339745)
12. Sun L, Vukicevic S, Baliram R, Yang G, Sendak R, McPherson J, Zhu LL, Iqbal J, Latif R, Natrajan A, Arabi A, Yamoah K, Moonga BS, Gabet Y, Davies TF, Bab I, Abe E, Sampath K, Zaidi M 2008 Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc Natl Acad Sci U S A 105:4289-4294. (Pubitemid 351754373)
13. Heemstra KA, Hamdy NA, Romijn JA, Smit JW 2006 The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid 16:583-591. (Pubitemid 44066265)
14. Belsing TZ, Tofteng C, Langdahl BL, Charles P, Feldt-Rasmussen U 2010 Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease? Nutr Metab (Lond) 7:72.
15. Yamane T, Kunisada T, Yamazaki H, Nakano T, Orkin SH, Hayashi SI 2000 Sequential requirements for SCL/tal-1, GATA-2, macrophage colony-stimulating factor, and osteoclast differentiation factor/osteoprotegerin ligand in osteoclast development. Exp Hematol 28:833-840. (Pubitemid 30411989)
16. Ando T, Latif R, Pritsker A, Moran T, Nagayama Y, Davies TF 2002A monoclonal thyroid-stimulating antibody. J Clin Invest 110:1667-1674. (Pubitemid 35424245)
17. Sanders J, Jeffreys J, Depraetere H, Evans M, Richards T, Kiddie A, Brereton K, Premawardhana LD, Chirgadze DY, Núñez Miguel R, Blundell TL, Furmaniak J, Rees Smith B 2004 Characteristics of a human monoclonal autoantibody to the thyrotropin receptor: Sequence structure and function. Thyroid 14:560-570. (Pubitemid 39097076)
18. Morshed SA, Latif R, Davies TF 2009 Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology 150:519-529.
19. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176. (Pubitemid 28180851)
20. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95:3597-3602.
21. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A 2000 Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 275:4858-4864. (Pubitemid 30108878)
22. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T 2000 Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/ RANKL-RANK interaction. J Exp Med 191:275-286.
23. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL 2000 TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481-1488. (Pubitemid 32038586)
24. Davies TF, Ando T, Lin RY, Tomer Y, Latif R 2005 Thyrotropin receptor-associated diseases: From adenomata to Graves disease. J Clin Invest 115:1972-1983. (Pubitemid 41134132)
25. Giusti M, Valenti S, Guazzini B, Molinari E, Cavallero D, Augeri C, Minuto F 2003 Circulating nitric oxide is modulated by recombinant human TSH administration during monitoring of thyroid cancer remnant. J Endocrinol Invest 26:1192-1197. (Pubitemid 38324736)
26. Sellitti DF, Dennison D, Akamizu T, Doi SQ, Kohn LD, Koshiyama H 2000 Thyrotropin regulation of cyclic adenosine monophosphate production in human coronary artery smooth muscle cells. Thyroid 10:219-225. (Pubitemid 30202407)
27. Klein M, Brunaud L, Muresan M, Barbé F, Marie B, Sapin R, Vignaud JM, Chatelin J, Angioï-Duprez K, Zarnegar R, Weryha G, Duprez A 2006 Recombinant human thyrotropin stimulates thyroid angiogenesis in vivo. Thyroid 16: 531-536. (Pubitemid 44066259)
28. Antunes TT, Gagnon A, Chen B, Pacini F, Smith TJ, Sorisky A 2006 Interleukin-6 release from human abdominal adipose cells is regulated by thyroid-stimulating hormone: Effect of adipocyte differentiation and anatomic depot. Am J Physiol Endocrinol Metab 290:E1140-E1144. (Pubitemid 43847897)
29. Vega D, Maalouf NM, Sakhaee K 2007 CLINICAL Review #: The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: Clinical implications. J Clin Endocrinol Metab 92:4514-4521. (Pubitemid 350223419)
30. Hofbauer LC, Kluger S, Kuhne CA, Dunstan CR, Burchert A, Schoppet M, Zielke A, Heufelder AE 2002 Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. J Cell Biochem 86:642-650. (Pubitemid 34839966)
31. Kim N, Kadono Y, Takami M, Lee J, Lee SH, Okada F, Kim JH, Kobayashi T, Odgren PR, Nakano H, Yeh WC, Lee SK, Lorenzo JA, Choi Y 2005 Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 202:589-595. (Pubitemid 41248411)
32. Arufe MC, Lu M, Kubo A, Keller G, Davies TF, Lin RY 2006 Directed differentiation of mouse embryonic stem cells into thyroid follicular cells. Endocrinology 147:3007-3015. (Pubitemid 43764636)
33. Ma R, Latif R, Davies TF 2009 Thyrotropin-independent induction of thyroid endoderm from embryonic stem cells by activin A. Endocrinology 150:1970-1975.